Table 2.

Treatment-emergent adverse event (TEAE).

System organ class	PlaceboN=9	Foralumab (10ug) N=6	Foralumab (50ug) N=6	Foralumab (250ug) N=6	Foralumab-all doses N=18
Subjects with at least one TEAE	2	5	5	2	12
Number of TEAEs by severity	3	15	9	3	27
Severity					27
Non-serious	3	15	9	3	27
Serious	0	0	0	0	0
Ear and labyrinth disorders					3
Non-serious	0	2	1	0	3
Serious	0	0	0	0	0
Gastrointestinal disorders					2
Non-serious	0	0	2	0	2
Serious	0	0	0	0	0
Immune system disorder					1
Non-serious	0	0	1	0	1
Serious	0	0	0	0	0
Infections and infestations					9
Non-serious	0	8	0	1	9
Serious	0	0	0	0	0
Injury, poisoning and procedural complications					1
Non-serious	0	1	0	0	1
Serious	0	0	0	0	0
Nervous system disorders					6
Non-serious	0	3	2	1	6
Serious	0	0	0	0	0
Skin and subcutaneous tissue disorder					5
Non-serious	3	1	3	1	5
Serious	0	0	0	0	0

Bold values are p<0.05.